Filing Flows › Cytosorbents (CTSO) › Q1 2026 › vs Q4 2025
Cytosorbents (CTSO) Q1 2026 vs Q4 2025 (quarter over quarter)
Cytosorbents's revenue fell $370K (-4%) from $9.2M in Q4 2025 to $8.9M in Q1 2026.
Cytosorbents, Q1 2026: revenue $8.9M (+2% year over year), operating margin -34.3%, net loss $5.1M, operating cash flow −$1.2M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.9M | $9.2M | −$370K | -4% |
| Net loss | $5.1M | $5.5M | −$368K | -7% |
| Costs & expenses | $14.0M | $14.7M | −$738K | -5% |
| Operating costs | $11.9M | $13.6M | −$1.7M | -13% |
| Interest & other, net | $2.1M | $1.1M | $973K | +88% |
| Cost of revenue | $2.7M | $2.4M | $304K | +13% |
| SG&A | $8.1M | $9.4M | −$1.3M | -14% |
| Operating cash sources | $5.1M | $5.5M | −$368K | -7% |
| Depreciation & amortization | $350K | $97K | $253K | +261% |
| Share-based compensation | $544K | $886K | −$342K | -39% |
| Working capital & other | $3.1M | −$311K | $3.4M | — |
| Cash used in operations | $1.2M | $4.8M | −$3.7M | -76% |
| Net loss absorbed | $5.1M | $5.5M | −$368K | -7% |
Questions
How much did Cytosorbents's revenue grow quarter over quarter in Q1 2026?
Cytosorbents's revenue fell $370K (-4%) from $9.2M in Q4 2025 to $8.9M in Q1 2026.